AstraZeneca: phase III trial confirms Brilinta potential
(CercleFinance.com) - AstraZeneca said that Brilinta sharply reduced the risk of stroke and death in patients who had an acute ischaemic stroke or transient ischaemic attack in a phase III trial.
Detailed results from the clinical trial showed that Brilinta used twice daily and taken with daily aspirin for 30 days reduced the rate of the primary composite endpoint of stroke and death by 17% compared to aspirin alone.
This was a "statistically significant and clinically meaningful reduction," the Anglo-Swedish drugmaker said.
AstraZeneca also said that Farxiga has been granted "fast track designation" to reduce the risk of hospitalisation for heart failure or cardiovascular death in adults following an acute myocardial infarction or heart attack.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Detailed results from the clinical trial showed that Brilinta used twice daily and taken with daily aspirin for 30 days reduced the rate of the primary composite endpoint of stroke and death by 17% compared to aspirin alone.
This was a "statistically significant and clinically meaningful reduction," the Anglo-Swedish drugmaker said.
AstraZeneca also said that Farxiga has been granted "fast track designation" to reduce the risk of hospitalisation for heart failure or cardiovascular death in adults following an acute myocardial infarction or heart attack.
Copyright (c) 2020 CercleFinance.com. All rights reserved.